Oral submucosal fibrosis (OSMF) is a precancerous disorder, characterized by
inflammation and progressive fibrosis of the submucosal tissue8, and transforms into a malignant tumor in 1.5–15% of all cases9. OSMF was first described as “Atropica idiopathica mucosae oris” in 1952 by Schwartz.
In spite of several efforts toward management and treatment of OSMF, late-stage diagnosis severely limits the therapeutic options for patients. Therefore, prognostic markers are extremely important. Moreover, lifestyle choices such as tobacco and alcohol abuse often result in dietary deficiencies that increase the risk of co-morbidities.
Effect of the drugs in the current study on the fibrosis induction in oral cells
was not significant for 3-day treatment, the reduction was mainly visible after day 7 of treatment which further increased till 14 days. This observation fits with the previous findings that oral fibrosis cells are stubbornly programmed to be transformed completely in fibrotic cells in a nearly irreversible manner. Interestingly Absogen, Abronym and their combinations with other drugs could not decrease fibrotic characters in a significant manner, the situation was similar for all the concentrations and incubation time points.
On the other hand, Zerilox, GC and Vindia were able to reduce the fibrotic characters individually as well as with all their combinations. Again, the effect was exerted mainly after 7 days of incubation period, but it was concentration dependent as well as treatment period dependent. The combination of all 3, Zerilox, GC and Vindia shown the highest reduction in fibrotic characters, where the range of % change was minimum 6.24% to maximum 53.99%. Oral fibrosis a growing issue in Indian subcontinent and in middle eastern countries, the potential of Zerilox, GC and Vindia must be studied further for signaling and molecular mechanisms.